{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:27:16Z","timestamp":1780514836371,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Kidney and life outcomes remain unsatisfactory in patients with microscopic polyangiitis (MPA). Appropriate treatment intensity must be provided to the appropriate patients. To identify severe cases early, we investigated the factors related to kidney and life outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included patients diagnosed with MPA based on myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) positivity and kidney histopathology results after kidney biopsies between January 1, 2021, and May 11, 2023, at 10 affiliated centers, including our hospital. Death, maintenance dialysis, and estimated glomerular filtration rate (eGFR)\u00a0&lt;\u00a015 after 6\u00a0months of treatment were defined as poor prognosis groups, and factors associated with these conditions were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 84 (36 men and 48 women) patients in this study. Median age was 73.8 (interquartile range: 71\u201381) years. After 6\u00a0months of treatment, the proportion of patients in the poor prognosis group was 16.7 %, with a mortality of 7.1 % and a poor kidney prognosis rate of 9.5 %. Area under the receiver operating characteristic curve showed that eGFR at 2\u00a0weeks had a comparable prognostic performance equal as eGFR at 4\u00a0weeks (area under the curve: 0.875 and 0.896, respectively). After adjustment by various factors, eGFR at 2\u00a0weeks was related with prognosis significantly (p\u00a0=\u00a00.031).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Kidney function 2\u00a0weeks after the start of treatment for MPA can predict prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-024-02522-6","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T17:01:29Z","timestamp":1717866089000},"page":"701-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognosis of microscopic polyangiitis is well predictable in the first 2 weeks of treatment"],"prefix":"10.1007","volume":"28","author":[{"given":"Akiko","family":"Owaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-688X","authenticated-orcid":false,"given":"Kazuhiro","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Koshi-Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"2522_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N, et al. Anca-associated vasculitis. Nat Rev Dis Prim. 2020;6:71.","journal-title":"Nat Rev Dis Prim"},{"key":"2522_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"2522_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med."},{"key":"2522_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","volume":"82","author":"RM Smith","year":"2023","unstructured":"Smith RM, Jones RB, Specks U, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomized controlled trial. Ann Rheum Dis. 2023;82:937\u201344.","journal-title":"Ann Rheum Dis"},{"key":"2522_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo BS, Schirmer JH, et al. EULAR recommendation for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30\u201347.","journal-title":"Ann Rheum Dis"},{"key":"2522_CR6","first-page":"248","volume":"32","author":"S Moiseev","year":"2017","unstructured":"Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transpl. 2017;32:248\u201353.","journal-title":"Nephrol Dial Transpl"},{"key":"2522_CR7","doi-asserted-by":"publisher","first-page":"c21","DOI":"10.1159\/000286346","volume":"115","author":"M Itabashi","year":"2010","unstructured":"Itabashi M, Takei T, Yabuki Y, et al. Clinical outcome and prognosis of antineutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115:c21-7.","journal-title":"Nephron Clin Pract"},{"key":"2522_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94:1177\u201388.","journal-title":"Kidney Int"},{"key":"2522_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628\u201336.","journal-title":"J Am Soc Nephrol"},{"key":"2522_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1046\/j.1523-1755.1999.00758.x","volume":"56","author":"IM Bajema","year":"1999","unstructured":"Bajema IM, Hagen EC, Hermans J, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751\u20138.","journal-title":"Kidney Int"},{"issue":"12","key":"2522_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/ckj\/sfad157","volume":"16","author":"C Bound\u2019hors","year":"2023","unstructured":"Bound\u2019hors C, Riou J, Fage N, et al. Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritis. Clin Kidney J. 2023;16(12):2530\u201341.","journal-title":"Clin Kidney J"},{"issue":"3","key":"2522_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ekir.2024.01.007","volume":"9","author":"R Takeda","year":"2024","unstructured":"Takeda R, Takahashi K, Kronbichler A, et al. Development of a kidney prognostic score in a Japanese cohort of patients with antineutrophil cytoplasmic autoantibody vasculitis. Kidney Int Rep. 2024;9(3):611\u201323.","journal-title":"Kidney Int Rep"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02522-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T09:03:33Z","timestamp":1718874213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02522-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Nagoya University Hospital (approval number: 2010\u20131135). Informed consent was obtained from all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}